SAGE-217

SAGE-217

  • March 2019 •
  • 20 pages •
  • Report ID: 5807972 •
  • Format: PDF
SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) is a novel, next-generation positive allosteric modulator that selectively binds synaptic and extrasynaptic gamma-aminobutyric acid-A (GABA-A) receptors and shares similar pharmacology properties to brexanolone.